Walleye Capital LLC Acquires New Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Walleye Capital LLC purchased a new position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 163,997 shares of the biotechnology company's stock, valued at approximately $5,494,000. Walleye Capital LLC owned 0.54% of AnaptysBio at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AnaptysBio by 10.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 32,884 shares of the biotechnology company's stock worth $1,102,000 after purchasing an additional 3,223 shares during the last quarter. BNP Paribas Financial Markets increased its position in AnaptysBio by 6,009.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 66,109 shares of the biotechnology company's stock valued at $2,215,000 after acquiring an additional 65,027 shares in the last quarter. FMR LLC grew its position in shares of AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after buying an additional 438,557 shares during the period. The Manufacturers Life Insurance Company grew its position in shares of AnaptysBio by 66.1% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 42,046 shares of the biotechnology company's stock worth $1,409,000 after buying an additional 16,734 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in AnaptysBio by 3.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 160,321 shares of the biotechnology company's stock valued at $5,371,000 after purchasing an additional 5,043 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ANAB shares. HC Wainwright cut their price target on shares of AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a research note on Wednesday, November 6th. Wedbush reaffirmed an "outperform" rating and set a $42.00 price target on shares of AnaptysBio in a research report on Thursday, November 14th. Guggenheim upped their price objective on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday, October 21st. JPMorgan Chase & Co. decreased their price objective on shares of AnaptysBio from $75.00 to $66.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. Finally, Truist Financial upped their price target on shares of AnaptysBio from $20.00 to $30.00 and gave the company a "hold" rating in a research note on Thursday, August 15th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $54.64.

AnaptysBio Trading Down 2.3 %

NASDAQ ANAB traded down $0.58 during mid-day trading on Monday, hitting $24.38. The company's stock had a trading volume of 1,073,906 shares, compared to its average volume of 357,664. The company's 50 day simple moving average is $27.91 and its 200 day simple moving average is $29.74. AnaptysBio, Inc. has a twelve month low of $14.70 and a twelve month high of $41.31. The firm has a market capitalization of $741.88 million, a price-to-earnings ratio of -4.01 and a beta of -0.24.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analysts' expectations of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, research analysts forecast that AnaptysBio, Inc. will post -6.02 EPS for the current year.

Insider Activity at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the transaction, the insider now owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This represents a 8.88 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now directly owns 4,744 shares in the company, valued at approximately $189,333.04. This represents a 72.03 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 22,440 shares of company stock worth $892,936 over the last quarter. 33.70% of the stock is owned by corporate insiders.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.